Cabaletta Bio Sees Unusually Large Options Volume (NASDAQ:CABA)
by Scott Moore · The Cerbat GemCabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) saw some unusual options trading on Thursday. Investors bought 3,428 call options on the stock. This represents an increase of approximately 83% compared to the typical daily volume of 1,871 call options.
Trending Headlines about Cabaletta Bio
Here are the key news stories impacting Cabaletta Bio this week:
- Positive Sentiment: CEO Steven Nichtberger purchased 45,000 shares (~$100.8k) and increased his stake to ~1.03M shares — a large, high‑profile insider buy that signals executive confidence. Read More.
- Positive Sentiment: Director Mark Simon bought 11,061 shares (~$25.2k), raising his holding by ~8.1% — another board‑level purchase reinforcing the insider buying trend. Read More.
- Positive Sentiment: General Counsel Michael Gerard and several other insiders (Shawn Tomasello, Steve Gavel, Gwendolyn Binder, David J. Chang) made purchases totaling tens of thousands of shares at ~$2.19–$2.27 each — broad participation across management/board suggests aligned bullish views. Read More. • Read More.
- Positive Sentiment: Press report: Cabaletta says it is accelerating its autoimmune CAAR‑T program and is targeting a 2027 FDA filing — a clear program milestone target that, if achieved, could materially de‑risk value for investors. Read More.
- Neutral Sentiment: Analyst landscape: several firms maintain buy ratings and a consensus “Moderate Buy” with an average price target (~$16.25), implying significant upside from current levels but reflecting long‑dated clinical risk. Read More.
- Neutral Sentiment: Institutional holders: select life‑science funds and asset managers have materially increased positions in past quarters — supportive for liquidity and longer‑term interest but not a near‑term catalyst. Read More.
- Negative Sentiment: Risk profile: Cabaletta is a clinical‑stage biotech with negative EPS, high beta and a multi‑year development path — the 2027 filing target is aspirational and clinical/regulatory setbacks would weigh on the stock. Read More.
Cabaletta Bio Stock Up 29.3%
Shares of Cabaletta Bio stock traded up $0.69 on Thursday, reaching $3.03. The company’s stock had a trading volume of 11,118,270 shares, compared to its average volume of 2,383,927. Cabaletta Bio has a 52-week low of $0.99 and a 52-week high of $3.67. The company has a market capitalization of $291.19 million, a P/E ratio of -1.19 and a beta of 3.25. The stock has a 50-day moving average price of $2.29 and a 200-day moving average price of $2.11.
Cabaletta Bio (NASDAQ:CABA – Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05. Sell-side analysts forecast that Cabaletta Bio will post -2.34 earnings per share for the current fiscal year.
Insider Activity at Cabaletta Bio
In related news, CEO Steven Nichtberger purchased 45,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The shares were bought at an average cost of $2.24 per share, with a total value of $100,800.00. Following the acquisition, the chief executive officer owned 1,031,483 shares of the company’s stock, valued at $2,310,521.92. This represents a 4.56% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Steve Gavel purchased 22,170 shares of the stock in a transaction dated Wednesday, January 21st. The stock was acquired at an average cost of $2.27 per share, for a total transaction of $50,325.90. Following the transaction, the insider owned 22,170 shares of the company’s stock, valued at approximately $50,325.90. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 127,668 shares of company stock worth $286,211. 11.25% of the stock is owned by insiders.
Institutional Investors Weigh In On Cabaletta Bio
A number of large investors have recently added to or reduced their stakes in the business. Bain Capital Life Sciences Investors LLC raised its position in shares of Cabaletta Bio by 250.5% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 9,677,125 shares of the company’s stock worth $14,709,000 after buying an additional 6,916,237 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in Cabaletta Bio by 142.9% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock worth $13,421,000 after buying an additional 5,195,285 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Cabaletta Bio by 147.4% during the second quarter. Jennison Associates LLC now owns 6,020,167 shares of the company’s stock valued at $9,151,000 after buying an additional 3,586,439 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in Cabaletta Bio during the 2nd quarter worth $3,036,000. Finally, Woodline Partners LP raised its position in shares of Cabaletta Bio by 75.2% during the 3rd quarter. Woodline Partners LP now owns 2,135,348 shares of the company’s stock worth $4,997,000 after buying an additional 916,884 shares in the last quarter.
Wall Street Analyst Weigh In
Several analysts recently weighed in on CABA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a report on Wednesday, October 8th. Cantor Fitzgerald boosted their target price on shares of Cabaletta Bio from $15.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Jefferies Financial Group started coverage on shares of Cabaletta Bio in a research report on Friday, October 10th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Cabaletta Bio in a research report on Friday, October 10th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Cabaletta Bio has an average rating of “Moderate Buy” and an average price target of $16.25.
Read Our Latest Report on CABA
About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.
The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.